Does Cosentyx Affect Female Fertility?
Cosentyx (secukinumab), an IL-17A inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, shows no evidence of impairing female fertility in animal studies or human data. Animal reproduction studies in rats and cynomolgus monkeys at doses up to 24 times the human exposure revealed no effects on fertility, including estrus cycling, implantation, or early embryonic development.[1][2]
What Do Clinical Studies and Postmarketing Data Say?
Human clinical trials and postmarketing surveillance, including over 20,000 pregnancies exposed to Cosentyx, report no fertility impairments in women. The prescribing information notes no fertility issues in females of reproductive potential, with no impact on ovarian function or ovulation observed.[1] Real-world registries like the Psoriasis Pregnancy Study confirm no fertility signals, though data focus more on pregnancy outcomes than preconception fertility.[2]
Can Women Planning Pregnancy Use Cosentyx?
No specific restrictions exist for women trying to conceive. The label advises discontinuing Cosentyx if pregnancy is confirmed (due to limited human pregnancy data), but fertility itself is unaffected. Women should discuss with their doctor, as underlying conditions like psoriasis may indirectly influence fertility more than the drug.[1][3]
Any Risks During Pregnancy or Breastfeeding?
While fertility is unimpaired, Cosentyx crosses the placenta, with higher exposure in the third trimester. Neonatal outcomes show no increased malformation risk, but live virus vaccines are contraindicated in exposed infants for up to 4 months post-birth. Breastfeeding data are limited; benefits vs. risks should be weighed.[1][2]
How Does Cosentyx Compare to Other Biologics on Fertility?
Unlike some older DMARDs (e.g., methotrexate, which suppresses fertility), Cosentyx and other IL inhibitors like Taltz (ixekizumab) have clean fertility profiles. TNF inhibitors (e.g., Humira) similarly show no fertility effects in women.[3]
[1] Cosentyx Prescribing Information, Novartis, accessed via FDA.gov.
[2] Safety of Secukinumab in Pregnancy and Lactation, Dermatology and Therapy (2022).
[3] DrugPatentWatch.com/drug/cosentyx (patent and clinical overview).